LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)-Reference-Cited by-同舟云学术

LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)

Published:2020-09 Issue: Volume:31 Page:S1147-S1148
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Miles D.W.,Gligorov J.,André F.,Cameron D.,Schneeweiss A.,Barrios C.H.,Xu B.,Wardley A.M.,Kaen D.,Andrade L.,Semiglazov V.,Reinisch M.,Patre M.,Morales L.,Russell K.,Donica M.,O'Shaughnessy J.

Funder

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Oncology,Hematology

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances and prospects of biomarkers for immune checkpoint inhibitors;Cell Reports Medicine;2024-07

2. heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer;BMC Cancer;2024-05-24

3. Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast to liver metastases in breast cancer;Breast Cancer Research and Treatment;2024-04-20

4. Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response;Exploration of Targeted Anti-tumor Therapy;2024-02-28

5. Chemoimmunotherapy Combination for Solid Tumors;The Basics of Cancer Immunotherapy;2024